TB-500 (Thymosin Beta-4): Definition

Detailed Explanation

TB-500 is a synthetic version of a naturally occurring 43-amino-acid peptide called thymosin beta-4 (Tβ4). Thymosin beta-4 was originally isolated from the thymus gland in the 1960s as part of the thymosin fraction 5 research program led by Allan Goldstein. It is the most abundant member of the beta-thymosin family and is present in virtually all nucleated cells, where it serves as the primary intracellular sequestering protein for monomeric G-actin.

By binding G-actin (globular actin) in a 1:1 complex, thymosin beta-4 regulates the polymerization of actin filaments — the cytoskeletal structures that drive cell migration, division, and shape changes. When cells are stimulated to move (as in wound healing), thymosin beta-4 releases its actin cargo, enabling rapid filament assembly at the leading edge of migrating cells. This mechanism underlies its wound-healing properties: thymosin beta-4 promotes keratinocyte and endothelial cell migration, angiogenesis, and reduces inflammatory cytokine production.

In preclinical studies, thymosin beta-4 has shown protective effects in cardiac ischemia (reducing scar size after heart attack), corneal wound healing (an ophthalmic formulation called RGN-259 advanced to Phase III trials), and dermal wound repair. TB-500 is the name commonly used in the peptide therapy community for the synthetic version. It is not FDA-approved as a drug. TB-500 should not be confused with TB4-Frag (Ac-SDKP), a tetrapeptide fragment of thymosin beta-4 that has distinct anti-fibrotic properties.

Key Facts

← Back to Full Dictionary